Free Trial

Indivior (INDV) Competitors

Indivior logo
$24.06 -0.09 (-0.39%)
As of 02:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INDV vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Indivior vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Indivior has a net margin of 6.65% compared to 180 Life Sciences' net margin of 0.00%. 180 Life Sciences' return on equity of 0.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Indivior 6.65%-86.28%16.26%

Indivior has a consensus price target of $19.60, suggesting a potential downside of 18.53%. Given Indivior's stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Indivior
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

60.3% of Indivior shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Indivior has higher revenue and earnings than 180 Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Indivior$1.19BN/A$2M$0.6238.80

In the previous week, Indivior had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Indivior and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.66 beat Indivior's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
180 Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Indivior
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Indivior beats 180 Life Sciences on 9 of the 11 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDV vs. The Competition

MetricIndiviorMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$2.49B$5.76B$9.55B
Dividend YieldN/A1.66%4.53%4.07%
P/E Ratio38.9822.4930.4325.11
Price / SalesN/A548.74392.2187.48
Price / Cash12.90173.7937.0358.50
Price / Book-9.555.259.016.20
Net Income$2M$31.83M$3.26B$265.38M
7 Day Performance3.83%0.56%1.00%-1.25%
1 Month Performance54.21%3.47%4.19%-0.81%
1 Year Performance94.79%9.45%28.39%18.83%

Indivior Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDV
Indivior
1.7608 of 5 stars
$24.06
-0.4%
$19.60
-18.5%
+96.5%$0.00$1.19B38.981,051
ATNFW
180 Life Sciences
N/A$0.01
-6.6%
N/A+3,378.3%$0.00N/A0.007Positive News
Gap Up
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
flat
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.45
+54.4%
N/AN/A$0.00$106.21K0.0040
ALVOW
Alvotech
N/A$1.33
+4.7%
N/A-66.3%$0.00$585.60M0.004Positive News
Gap Up
ARAV
ARAVIVE
N/A$0.04
flat
N/AN/A$0.00$9.14M0.0020High Trading Volume
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.06
flat
N/AN/A$0.00N/A0.0015Gap Down
BFRIW
Biofrontera
N/A$0.14
flat
N/A+137.6%$0.00$38.00M0.0070Positive News
BTMDW
biote
N/A$0.01
+21.0%
N/A-98.1%$0.00$199.07M0.00N/AGap Up
High Trading Volume
BCTXW
BriaCell Therapeutics
N/A$0.03
-5.1%
N/A-89.0%$0.00N/A0.008Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:INDV) was last updated on 8/21/2025 by MarketBeat.com Staff
From Our Partners